FDA’s Benefit/Risk Framework Turns 10: A Quietly Critical Innovation
Executive Summary
In finalizing a guidance on its approach to the fundamental benefit-risk assessment for new drug reviews, US FDA affirms the central role of the qualitative benefit-risk framework tool that was rolled out a decade ago.